Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2006

Heinrich Michael C, McArthur Grant A, Demetri George D, Joensuu Heikki, Bono Petri, Herrmann Richard, Hirte Hal, Cresta Sara, Koslin D Bradley, Corless Christopher L, Dirnhofer Stephan, van Oosterom Allan T, Nikolova Zariana, Dimitrijevic Sasa, Fletcher Jonathan A

Abstract excerpt

PURPOSE: To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent. PATIENTS AND METHODS: Nineteen patients with AF were treated with imatinib (800 mg/d) as part of a phase II clinical study. Tumor specimens were analyzed for mutations of KIT, PDGFRA, PDGFRB, and CTNNB1 (beta-catenin). Tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Becaplermin
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Desmoid Tumors

Share to Platelet-Derived Growth Factor

Share to Positron-Emission Tomography

Share to Proto-Oncogene Proteins c-sis

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Receptor, Platelet-Derived Growth Factor beta

Source

Identifiers

PMID: 16505440
DOI: 10.1200/JCO.2005.04.0717

Genes

PDGFRB
KIT
PDGFRA
CTNNB1
APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).PMID 16505440Read ↗

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.Semantic proximity Read ↗

Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.Semantic proximity Read ↗

Efficacy of auranofin as an inhibitor of desmoid progression.Semantic proximity Read ↗

Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.Semantic proximity Read ↗

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).Semantic proximity Read ↗

Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).Semantic proximity Read ↗

Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in ChordomasSemantic proximity Read ↗

Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations.Semantic proximity Read ↗

Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.Semantic proximity Read ↗

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.Semantic proximity Read ↗

Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.